Is SNY a buy according to AI stock analysis?

SNY is not an automatic buy according to this AI stock analysis. Sanofi has profitable franchises and a modest valuation snapshot, but a decision depends on confidence in Dupixent durability, launches, pipeline delivery, pricing, and an adequate margin of safety.

What is the SNY AI stock forecast?

The SNY AI stock forecast is scenario-based rather than a precise prediction. The audited three-year framework shows a bearish area near $30, a base area near $50, and a bullish area near $65 before dividends, with results driven by earnings growth and valuation multiples.

What technical levels matter for SNY?

The key SNY technical levels are support near $43.40 to $43.50, major support near $40.89, and resistance near the $46.82 200-day moving average. These July 10, 2026 snapshot levels should be checked against a live chart before use.

Can AI predict SNY stock price?

No, AI cannot reliably predict stock prices. It can organize reported data, identify assumptions, calculate scenarios, and flag risks, but it cannot know clinical outcomes, policy choices, currency moves, competitive actions, or future market sentiment.

How should I use this SNY AI trading strategy?

Use this SNY AI trading strategy as a research checklist, not a personalized recommendation. Define a setup, position size, invalidation level, and monitoring plan, then refresh the chart and company disclosures before making any trading decision.

Why does Dupixent matter so much to Sanofi?

Dupixent matters because it generated €15.714 billion in FY2025, or 36.0% of Sanofi net sales. Its growth supports the earnings case, while its concentration makes competition, pricing, reimbursement, and lifecycle management central risks.

Sanofi research snapshot

SNY AI Stock Analysis

SNY AI stock analysis currently views Sanofi as a profitable global biopharma company whose growth is increasingly tied to Dupixent, new launches, and immunology execution. At the July 10, 2026 data cutoff, SNY last closed at $43.90 and the reported market capitalization was $104.93 billion. The setup combines low current valuation multiples with concentration, patent, pricing, pipeline, and leadership-transition risks. This page is informational research, not investment advice.

Current price

$43.90

Market cap

$104.93 billion

AI score

68 / 100

Rating

Profitable immunology leader with product concentration and execution risk

Trend status

Near the 50-day average and below the 200-day average, with neutral momentum

Data cutoff (updated weekly)

July 10, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: A-level information richness. Sanofi publishes audited annual reports, quarterly results, product sales, pipeline updates, ADR terms, and capital-allocation disclosures, with broad third-party market-data coverage.
bias Check: The main AI bias risk is to treat rapid Dupixent growth and a low trailing multiple as sufficient proof of value. This review tests that narrative against Dupixent concentration, patent and competition risk, reimbursement pressure, pipeline setbacks, currency, acquisitions, and the change in chief executive.
ai Confidence: High for reported FY2025 and Q1 2026 results, ADR-share mechanics, market-cap arithmetic, and the technical snapshot. Medium for forward earnings and price scenarios because drug competition, trial results, pricing, and currency can change the outcome quickly.
investment Certainty: Medium-low. The business produces cash and has visible growth products, but an investment conclusion depends on whether launches and pipeline assets can diversify earnings before Dupixent faces more mature competition.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Sanofi converts research, clinical development, regulatory approvals, biologics manufacturing, and commercial access into recurring sales of medicines and vaccines for serious disease.	High
Moat	Patents, clinical evidence, physician trust, global manufacturing, regulatory know-how, and distribution support the franchise, but product exclusivity is finite and payer power matters.	Medium-high
Management	Capital allocation includes launches, acquisitions, and a €1 billion 2026 buyback plan. The CEO transition to Belén Garijo adds an execution item to monitor.	Medium
Financial trend	FY2025 company net sales were €43.626 billion, up 9.9% at constant exchange rates, and business EPS was €7.83. Q1 2026 net sales reached €10.509 billion and business EPS was €1.88.	High
Valuation	The audited July 9 snapshot produces about 12.3x trailing ADR EPS and 10.8x free cash flow per ADR. Low multiples do not remove the risk that future earnings growth falls short.	Medium-high
Technical trend	SNY was near its 50-day average of $43.47 and below its 200-day average of $46.82, while RSI near 51 was neutral. The longer-term chart needs confirmation.	Medium
Risk level	Risk is medium-high because Dupixent represented 36.0% of FY2025 net sales, and pharmaceutical earnings remain exposed to competition, patents, pricing, pipeline, regulation, and currency.	High
AI confidence	Reported facts and current market inputs are well documented, but AI cannot turn clinical outcomes or investor sentiment into a dependable price prediction.	High data confidence
Investment certainty	Medium-low certainty. A potential margin of safety exists only if growth from Dupixent, launches, vaccines, and the pipeline offsets future concentration and pricing pressure.	Medium-low

SNY AI stock forecast

SNY AI Stock Forecast Scenarios

The SNY AI stock forecast uses audited scenario math around the $43.90 July 9 close and $3.58 trailing ADR EPS. A three-year framework produced a bearish area near $30, a base area near $50, and a bullish area near $65. These are conditional scenarios before dividends, not price promises.

Bullish case

$62 to $68 over three years

More likely if Dupixent keeps growing, recent launches scale, vaccines recover, the pipeline produces differentiated approvals, 2026 guidance is met, and investors sustain an earnings multiple near 13x.

Base case

$47 to $53 over three years

More likely if business EPS compounds near 8% annually, buybacks reduce the share count, pricing and currency remain manageable, and the market values SNY near an 11x earnings multiple.

Bearish case

$28 to $33 over three years

More likely if Dupixent growth slows materially, trial or launch execution disappoints, price pressure or generics intensify, acquisitions dilute returns, or the market compresses the multiple toward 8x.

SNY AI technical analysis

SNY AI Technical Analysis

SNY AI technical analysis is neutral to cautious at the July 10, 2026 cutoff. StockAnalysis recorded a July 9 close of $43.90, a 50-day moving average of $43.47, a 200-day moving average of $46.82, RSI of 51.25, and a 20-day average volume of 4.18 million shares. These are chart snapshots, not forecasts.

Level	Value	Why it matters
Current price	$43.90	StockAnalysis recorded the July 9, 2026 closing price. The July 10 research cutoff occurred before that US market session had closed.
Near support	$43.40 to $43.50	The 50-day moving average was $43.47. Holding this area would keep a short-term stabilization case intact.
Major support	$40.90 to $41.00	The reported 52-week low was $40.89. A sustained break below this zone would weaken the range-trading thesis.
Near resistance	$46.80 to $47.00	The 200-day moving average was $46.82. Reclaiming it would improve the longer-term trend read.
50-day moving average	$43.47	Price was modestly above this short-term reference on July 9, but one close does not establish a trend.
200-day moving average	$46.82	Price remained below this longer-term reference, leaving overhead resistance in place.
Momentum	RSI 51.25	RSI was close to neutral. It did not signal either a confirmed oversold reversal or strong momentum.
Volume	20-day average 4.18 million shares	Compare any move through support or resistance with this recent activity level, especially around results and clinical news.
Volatility	$40.89 to $52.68 52-week range	A low beta does not prevent event-driven gaps in an individual biopharma ADR.
Invalidation	Sustained close below $40.89	A break below the reported 52-week low would invalidate this range-based technical framework and require a fresh chart review.

SNY AI trading strategy

SNY AI Trading Strategy Framework

The SNY AI trading strategy is a rules-based research framework for a large biopharma ADR. It is not personal advice. Refresh the live chart, company filings, clinical disclosures, and position-sizing rules before acting.

Trend-following setup

Wait for SNY to hold above the $43.40 to $43.50 area and then reclaim the $46.80 to $47.00 200-day-average zone with stronger volume. That sequence would provide better trend confirmation than buying a single up day.

A sustained close below $40.89 or a material deterioration in sales, guidance, or clinical evidence should invalidate the setup.

Mean-reversion setup

If SNY revisits support, compare the valuation with the next results, Dupixent sales, launch momentum, vaccines, and management guidance before treating a lower price as an opportunity.

Do not average down without a predefined loss limit. Product, regulatory, and trial events can gap an ADR through ordinary stop levels.

Fundamental monitor

Track Dupixent, pharma-launch, and vaccine sales; business EPS guidance; R&D productivity; pipeline readouts; net debt; buybacks; pricing and reimbursement; generic exposure; and the leadership transition.

Reduce confidence if growth relies more heavily on one product, acquisitions, or buybacks while new-product revenue, cash generation, and pipeline productivity weaken.

Investment research summary

Four-master Research Compression

Business essence

Sanofi turns research, clinical evidence, regulatory approvals, manufacturing, and commercial access into recurring sales of specialty medicines and vaccines. Patients, physicians, health systems, and payers pay when a therapy has differentiated clinical value and reimbursement support.

Moat

The moat combines patents, biologics and vaccine manufacturing, clinical evidence, regulatory capability, trusted brands, physician relationships, and global distribution. It is strongest in differentiated products and weaker as exclusivity expires or similar therapies reach the market.

Munger risk inversion

The thesis can fail if Dupixent concentration rises further, competition or reimbursement reduces realized prices, trials disappoint, launches do not scale, vaccine demand softens, acquisitions fail to earn their cost of capital, or currency and debt weigh on owner returns.

Management

Management has focused capital on R&D, launches, acquisitions, and share repurchases. The incoming CEO must show that this allocation can diversify earnings, sustain research productivity, and preserve financial flexibility rather than simply extend a product cycle.

Industry trend

Immunology, specialty care, rare disease, oncology, and adult vaccines address durable medical demand. The industry also faces payers with purchasing power, policy intervention, trial risk, manufacturing constraints, and recurring patent cycles.

Valuation and margin of safety

At the July 9 close, the verified snapshot was about 12.3x trailing ADR EPS and 10.8x free cash flow per ADR. That valuation may offer room for error only if growth products and pipeline assets replace mature-product pressure without eroding returns on capital.

Source-backed data

SNY Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
SNY price and market capitalization	$43.90 July 9 close and $104.93 billion reported market cap	StockAnalysis SNY statistics	July 10, 2026
ADR mechanics and market-cap verification	One ordinary Sanofi share equals two ADSs. $43.90 x 2.39 billion ADS equivalents equals $104.92 billion, a 0.01% difference from the reported market cap.	Sanofi ADR program and financial_rigor.py market-cap verification	July 10, 2026
FY2025 net sales and business EPS	€43.626 billion net sales, up 9.9% at CER, and €7.83 business EPS	Sanofi FY2025 results	July 10, 2026
FY2025 revenue reconciliation	StockAnalysis reports €46.716 billion standardized revenue. This differs from company net sales by 7.1%, so this page uses company-reported net sales rather than mixing the two measures.	StockAnalysis SNY financials	July 10, 2026
FY2025 IFRS net income and cash	€7.813 billion net income attributable to equity holders and €7.657 billion cash and equivalents, each cross-checked with StockAnalysis	Sanofi Form 20-F 2025	July 10, 2026
Q1 2026 results and guidance	€10.509 billion net sales, €1.88 business EPS, and high-single-digit 2026 sales growth guidance at CER with business EPS expected to grow slightly faster than sales	Sanofi Q1 2026 results	July 10, 2026
Dupixent concentration	€15.714 billion of FY2025 sales, representing 36.0% of net sales	Sanofi Form 20-F 2025	July 10, 2026
Technical and valuation snapshot	50-day average $43.47, 200-day average $46.82, RSI 51.25, trailing PE 12.05x, and reported P/FCF 10.70x	StockAnalysis SNY statistics	July 10, 2026

Frequently Asked Questions

Read the NVS AI stock analysis View the NVO AI stock forecast Explore the AZN AI technical analysis Use the AI Stock Picker Build an AI trading strategy Screen stocks by your criteria

This SNY page is an informational research tool, not investment advice or a recommendation to buy or sell securities. Forecasts are conditional scenarios based on available data and assumptions. They can be wrong, and market, clinical, regulatory, pricing, currency, and company-specific events can cause losses.